AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX Operating Cash Flow
Cash generated by the company's core business operations during the period.
AN2 Therapeutics, Inc.NASDAQ: ANTX
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $12.07M (cash outflow) rose 13.6% year over year, ahead of the -26.0% change in trailing-twelve-month operating cash flow. Sequentially, it rose 130.6% from the prior quarter. Over 3 fiscal years it compounded at -3.8% a year.
Context
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +13.6% holds above the trailing-twelve-month pace of -26.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (29.83M) USD
- Year-over-year change
- +39.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.83M) | +39.4% |
| FY2024 | 2024-12-31 | (49.26M) | +7.6% |
| FY2023 | 2023-12-31 | (53.29M) | -59.2% |
| FY2022 | 2022-12-31 | (33.46M) | -63.4% |
| FY2021 | 2021-12-31 | (20.48M) | — |
Operating Cash Flow vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's LTM Mar 2026 operating cash flow of $31.28M is the 3rd largest of the 6 companies compared; the peer median is $27.4M.
- Its year-over-year change of -26.0% is the 4th highest of 6, against a peer median of -21.0%.
- Over three fiscal years its annual growth of -3.8% compares with a peer median of +5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $68.21M | +123.6% | +24.0% | — | |
| LTM Mar 2026 | $47.1M | -21.0% | +5.6% | — | |
| LTM Mar 2026 | $31.28M | -26.0% | -3.8% | — | |
| LTM Mar 2026 | $27.4M | -58.3% | +45.2% | 51.0% | |
| LTM Jun 2026 | $23.22M | +51.7% | -8.6% | 23218.0% | |
| LTM Mar 2026 | $14.11M | -73.7% | -1.9% | 38.0% | |
| Peer median (excluding ANTX) | $27.4M | -21.0% | +5.6% | 51.0% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 974K | 4.39M | 8.41M | 8.34M | 6.25M |
| Change in Working Capital | 32K | 3.72M | 5.83M | (3M) | 164K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 417K | 2.5M | 553K | 641K | (296K) |
| Other Working Capital | (385K) | 1.22M | 5.28M | (3.64M) | 460K |
| Other Non-Cash Items | 53K | (615K) | (2.8M) | (3.28M) | (1.07M) |
| Operating Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.27M) | (93.84M) | (132.18M) | (46.75M) | (46.19M) |
| Sales of Investments | 27.25M | 72.07M | 88.9M | 101.34M | 74.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.02M) | (21.77M) | (43.28M) | 54.59M | 28.31M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 70.37M | 84.53M | 372K | 113K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.2M) | (11K) | 465K | 0 | 0 |
| Financing Cash Flow | 78.54M | 70.36M | 84.99M | 372K | 113K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.03M | 15.12M | (11.57M) | 5.7M | (1.41M) |
| Free Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.